Cerebrovascular diseases and cardiovascular diseases mainly threaten the aging population. Notably, neuro-co-cardiological disease is the coexisting conditions of cerebrovascular and cardiological diseases. In a narrow sense, neuro-co-cardiological disease is the coexisting conditions in which vessels in both the brain and the heart are pathologically involved, primarily caused by atherosclerosis. By 2020, approximately 300 million people in China will suffer from cerebrovascular and cardiological diseases. More than half of stroke patients will suffer from stroke-induced heart damage, and more than 1/5 patients with coronary heart diseases may have potential cerebrovascular diseases. Thus, there may be a large population at risk for neuro-co-cardiological diseases in China. In particularly, the majority of this population with high risk of neuro-co-cardiological diseases is the elderly. Because of high mortality, poor prognosis and lacking effective treatment strategy, neuro-co-cardiological diseases are notable challenges in the new epoch. In this research topic, we will focus on five key questions: (1) The epidemiological nature of neuro-cardiovascular diseases is unclear. (2) How should patients with neuro-co-cardiological diseases be managed? (3) Who suffer from neuro-co-cardiological diseases? (4) Who will develop a neuro-co-cardiological disease? (5) The new therapeutic target for neuro-co-cardiological diseases. We want to receive the strong collaboration works among neurosurgeons, neurologists, and cardiologists, which aims to explore the appropriate management protocols and treatment strategies for neuro-co-cardiological diseases. In addition, we also appreciate large multi-omics studies, which are anticipated to generate additional treatment strategies and therapeutic targets for neuro-co-cardiological diseases. Focusing on the accurate treatment of neuro-co-cardiological diseases, this research topic is the first try to explore the Chinese approach to managing neuro-co-cardiological diseases patients in the new epoch.
Cerebrovascular diseases and cardiovascular diseases mainly threaten the aging population. Notably, neuro-co-cardiological disease is the coexisting conditions of cerebrovascular and cardiological diseases. In a narrow sense, neuro-co-cardiological disease is the coexisting conditions in which vessels in both the brain and the heart are pathologically involved, primarily caused by atherosclerosis. By 2020, approximately 300 million people in China will suffer from cerebrovascular and cardiological diseases. More than half of stroke patients will suffer from stroke-induced heart damage, and more than 1/5 patients with coronary heart diseases may have potential cerebrovascular diseases. Thus, there may be a large population at risk for neuro-co-cardiological diseases in China. In particularly, the majority of this population with high risk of neuro-co-cardiological diseases is the elderly. Because of high mortality, poor prognosis and lacking effective treatment strategy, neuro-co-cardiological diseases are notable challenges in the new epoch. In this research topic, we will focus on five key questions: (1) The epidemiological nature of neuro-cardiovascular diseases is unclear. (2) How should patients with neuro-co-cardiological diseases be managed? (3) Who suffer from neuro-co-cardiological diseases? (4) Who will develop a neuro-co-cardiological disease? (5) The new therapeutic target for neuro-co-cardiological diseases. We want to receive the strong collaboration works among neurosurgeons, neurologists, and cardiologists, which aims to explore the appropriate management protocols and treatment strategies for neuro-co-cardiological diseases. In addition, we also appreciate large multi-omics studies, which are anticipated to generate additional treatment strategies and therapeutic targets for neuro-co-cardiological diseases. Focusing on the accurate treatment of neuro-co-cardiological diseases, this research topic is the first try to explore the Chinese approach to managing neuro-co-cardiological diseases patients in the new epoch.
